Royal Bank Of Canada Red Hill Biopharma Ltd. Transaction History

Royal Bank Of Canada

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.14 - $695.9 $58 - $292,973	421 Added 9.73%	4,750 $0
Q3 2022 Nov 14, 2022	BUY	$0.5 - $523.8 $1,500 - $1.57 Million	3,000 Added 225.73%	4,329 $3,000
Q2 2022 Aug 15, 2022	SELL	$0.63 - $2.58 $170 - $699	-271 Reduced 16.94%	1,329 $1,000
Q1 2022 May 16, 2022	SELL	$1.65 - $3.12 $2,651 - $5,013	-1,607 Reduced 50.11%	1,600 $4,000
Q4 2021 Feb 14, 2022	SELL	$2.31 - $5.85 $4,887 - $12,378	-2,116 Reduced 39.75%	3,207 $8,000
Q3 2021 Nov 15, 2021	SELL	$4.55 - $10.36 $445 - $1,015	-98 Reduced 1.81%	5,323 $25,000
Q2 2021 Aug 16, 2021	BUY	$5.98 - $7.51 $32,417 - $40,711	5,421 New	5,421 $38,000

40.4K

Ticker RDHL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 63,823,500
Market Cap $465M
Description
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.